Control Bionics Ltd. · ASX:CBL
Control Bionics — Investor Presentation (September 2024)
36 slides from Control Bionics's investor presentation, Sep 19, 2024
Slide 1: Next-generation assistive technology and data measurement
Next-generation assistive technology and data measurement INVESTOR PRESENTATION SEPTEMBER 2024 CONTROLBIONICS.COM | ASX:CBL
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or
Slide 3: Proven core technology now with infinite possibilities
INTRODUCTION Proven core technology now with infinite possibilities We are empowering communication and enhancing lives with a vision to revolutionise medicine, sports science, rehabilitation and more with our next- generation EMG technology
Slide 4: On the cusp of rapid global growth
INTRODUCTION On the cusp of rapid global growth A proven medical device company with sizeable global sales of core products that we design and manufacture 20 years of Regulatory Core business Blue sky and Many levers for Near cash flow expertise with our clearance and continues to grow diversificati
Slide 5: EMG technology is at the heart of our solutions
INTRODUCTION EMG technology is at the heart of our solutions An EMG signal is Our patented code detected. creates a “switch” to operate devices Your brain sends a To move your finger, Our core IP uses smart Users can type, generate thought like “move my an electrical signal is algorithms to detect,
Slide 6: The evolution of our core IP
INTRODUCTION The evolution of our core IP Smaller, wireless and wearable NEUROEDUCATOR NEUROSTRIP One of the first prototype systems in A wireless, wearable NeuroNode was Just launched in 2023, the NeuroStrip the NeuroEDUCATOR series was first launched in 2017. Using our IP, weighs less than a piece
Slide 7: Solutions
Solutions Assistive Communication Assistive Mobility Data Measurement
Slide 8: Core products and those newly launched
PRODUCT OVERVIEW Core products and those newly launched Currently assisting those disabled and leaping to new untapped markets CUSTOMERS CURRENT CORE PRODUCTS NEW PRODUCTS Disabled and diseased Speech-generating solutions with flexible access methods (touch, eye, EMG) Standalone EMG and spatial acce
Slide 9: Our fastest near term path to growth
ASSISTIVE COMMUNICATION Our core IP remains innovative and without major competition even today Our fastest near term path to growth Those with degenerative neurological conditions, spinal cord injuries, cerebral palsy, and other conditions with movement restrictions can now access a computer, phone
Slide 10: Our flagship product is the world's fastest, lowest-fatigue eye-tracking system
ASSISTIVE COMMUNICATION Our flagship product is the world’s fastest, lowest- fatigue eye-tracking system, combining a camera, computer and NeuroNode (EMG/spatial) control This 3 in 1 solution suits those living with paralysis and loss of speech. Unlike other technologies, no movement is required to
Slide 11: A voice for those without
ASSISTIVE COMMUNICATION PRODUCT SUITE A voice for those without Bundle with a NeuroNode for faster, less tiring and easier communication USER TYPES A UnoTouch upgrade Includes all 3 access types Entry level access for Entry level for those who A user’s condition will determine the type of those who
Slide 12: Why our communication solutions are better
ASSISTIVE COMMUNICATION Why our communication solutions are better Other Providers Control Bionics Benefit to the customer Require a keyboard, Uses EMG and/or eye tracking. Proven to be both faster and less fatiguing in multiple studies. It mouse, joystick, also reduces repetitive strain injuries an
Slide 13: The world's first autonomous wheelchair
ASSISTIVE MOBILITY The world’s first autonomous wheelchair Partnering with Deakin University, we made the world’s first upgrade for powered wheelchairs, so the user’s intentions can control them. DROVE is a patent pending module that retrofits powered wheelchairs. Its technology helped us rank 4th i
Slide 14: The new NeuroStrip is a game-changer
BEYOND ASSISTIVE TECHNOLOGY The new NeuroStrip is a game-changer We are on a path to revolutionise new markets such as Market strategy: health diagnostics, sports science, critical care and more Enter those with the fastest, lowest- with the new miniaturisation of our world-class, award- cost access
Slide 15: NeuroStrip features and benefits
BEYOND ASSISTIVE TECHNOLOGY NeuroStrip features and benefits FEATURE BENEFIT Small, light, flexible and non-invasive. Increased choice of placement where At 3g, it weighs less than a piece of you want to switch with, monitor or NeuroStrip paper and is 4cm long. improve. It’s also easy to use. With n
Slide 16: Regulatory approvals
PRODUCT Regulatory approvals US Australia Japan UK Europe Regulatory Scheme FDA TGA PMDA MHRA CE Mark NeuroNode DROVE NeuroStrip * May require further approvals if the product use materially changes Approved Pending or near-term application Yet to be approved
Slide 17: Assistive Technology Market
Assistive Technology Communication Market Mobility
Slide 18: Our users
Our users Our devices help people of all ages living with conditions like ALS/Motor Neuron Disease (MND), Spinal Muscular Atrophy, Cerebral Palsy, and Spinal Cord Injury to control communication technology US AND AUSTRALIAN Amyotrophic Lateral Sclerosis (ALS) SALES BY CONDITION 25% Other “Since star
Slide 19: Minimum $1bn global market opportunity p.a.
Minimum $1bn global The new US insurance code Exclusive UK and Ireland approved in August 2024 Distribution Agreement opens up significant growth market opportunity p.a. signed with SmartBox (~70% opportunities with a new US market share) in Sep-24. wholesale strategy. An underserved niche market wi
Slide 20: Minimum $100 million market opportunity p.a.
Minimum $100 million market opportunity p.a. This is a new market for us where our add-on module to powered wheelchairs allows users to independently and safely navigate their homes The market opportunity is based on a 1% penetration of new global annual sales. 2 million Powered wheelchairs sold The
Slide 21: Current Business Model
Current Business Model A retail business model where our sales team work with prescribers to offer just assistive communication solutions.
Slide 22: The market's most personalised solution
ASSISTIVE COMMUNICATION The market’s most OUR PRESCRIBERS Prescribers demonstrate and recommend our solutions. They include Speech personalised solution Language Pathologists (SLPs), industry bodies, clinics, schools, hospitals and more LANGUAGE SYSTEM Our catalogue of synthetic voices, library of s
Slide 23: Funding overview
ASSISTIVE COMMUNICATION Funding overview At least 75% of our sales are Other USA AUSTRALIA through a person’s insurer 8% other 13% Federal 35% Medicare / 3rd Party Billing* Medicaid / 29% Veteran Affairs / STAPP (Texas) Private pay Private Insurance NDIS National Disability 12% 87% Insurance Scheme
Slide 24: Growth Strategy
Growth Strategy A new wholesale business model where we work with resellers and partners to offer more products with more uses in more geographical locations, generating new income streams and recurring revenue.
Slide 25: New wholesale strategy for growth
GROWTH STRATEGY OUR SOLUTIONS RESELLER OR New wholesale USER PARTNER strategy for growth SOFTWARE HARDWARE SUPPORT 24/7 Continued innovation NEUROSTRIP means we can further diversify the use of our NEURONODE ADVANTAGE DROVE ADVANTAGE NEUROSTRIP ADVANTAGE products and enter new Quicker to market Worl
Slide 26: Multiple levers for growth
GROWTH STRATEGY Multiple levers for growth CURRENT SALES STATUS NEW GEOGRAPHIES NEW CHANNEL PARTNERS NEW USE TYPE Japan was the first market Our next focus is the UK and Currently building distributor No - assistive for our new NeuroNode select continental European partnerships where our strong pate
Slide 27: Blue sky growth strategy with NeuroStrip
GROWTH STRATEGY Blue sky growth strategy with NeuroStrip USE TYPE FOR WHAT OUTCOME EASE OF MARKET ENTRY SELLING POINTS REGULATORY CURRENT BUSINESS / PRODUCT READINESS REQUIREMENTS DEVELOPMENT OPPORTUNITIES CBL has existing track record None In discussions with existing Sports science sEMG is used to
Slide 28: Blue sky growth strategy with NeuroStrip
GROWTH STRATEGY Blue sky growth strategy with NeuroStrip USE TYPE FOR WHAT OUTCOME EASE OF MARKET ENTRY SELLING POINTS REGULATORY CURRENT BUSINESS / PRODUCT READINESS REQUIREMENTS DEVELOPMENT OPPORTUNITIES Dysphagia sEMG biofeedback is used to Established market however new Lightweight, wireless, Mi
Slide 29: Roadmap
GROWTH STRATEGY Roadmap Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 DROVE TGA approval New US insurance code Japan breakeven expected Final tranche of US FDA submission for approved for NeuroNode, research grant payment DROVE enabling a new US wholesale First EU sales for for DROVE NeuroStrip customer s
Slide 30: Financial Performance
CONTROL BIONICS. Financial Performance
Slide 31: Record sales pipeline, building FY25 momentum
FINANCIALS REVENUE (A$ m) EBITDA ($A m) 6 5 0 -1 Record sales pipeline, 4 -2 building FY25 momentum 3 -3 FY24 revenue hit by ~$1M in NDIS delays. It’s 2 -4 improving with record processing in Aug-24 from our 1 -5 largest-ever backlog. 0 2021 2022 2023 2024 -6 2021 2022 2023 2024 Record Q4 results in
Slide 32: Continue to focus on growth, diversification and innovation
FINANCIALS Continue to focus on growth, diversification and innovation Goal: Achieve near-term EBITDA-positive operations in all key geographic markets for our primary disability business. Plan for FY25: Diversify into new products and markets to drive additional growth. Diversifying with NeuroStrip
Slide 33: Company
CONTROL BIONICS. Company
Slide 34: Experienced leadership
PEOPLE Experienced leadership BOARD Over 20 years experience in accounting, auditing and finance roles in the United States and Australia Previously held senior finance positions with multi- national ASX-listed and technology start-up entities Shannon Boothroyd Holds both Chartered Accountant (Austr
Slide 35: Corporate Summary
Corporate Summary FINANCIAL INFORMATION TOP SHAREHOLDERS Phoenix Development 15.69% Share price (13/9/24) A$0.08 Nightingale Partners 10.46% Shares on issue (15/8/24) 209.3 million Peter Shann Ford 10.04% Market capitalisation A$16.7 million Cash (30/06/24) A$0.98 million Top 20 hold 70.5% of shares
Slide 36: Get in touch
Get in touch COMPANY INVESTOR RELATIONS JEREMY STEELE JOE DURAK CEO EXECUTIVE DIRECTOR & FOUNDER CONTROL BIONICS LYNX ADVISORS jsteele@controlbionics.com joe@lynxadvisors.com.au +61 433 229 470 +61 414 465 582 CONTROLBIONICS.COM | ASX:CBL
Control Bionics — Investor Presentation (September 2024) on 6ix